Stockreport

MATEON’S GLOBAL STUDY FOR OT-101/ TGF-ß INHIBITOR AGAINST COVID-19 ENROLLS AND TREATS ITS FIRST PATIENT

MATEON THERAPEUTICS  (MATN) 
Last mateon therapeutics earnings: 11/19 05:25 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.mateon.com
PDF -FPI FOR C001 PHASE 2 TRIAL AGAINST COVID-19 AGOURA HILLS, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MA [Read more]